PARIS--(BUSINESS WIRE)--Regulatory News:
Pixium Vision (Paris:PIX) (FR0011950641 - PIX), a company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announced that its 2017 Registration Document has been filed to the Autorité des Marchés Financiers (AMF).
The Registration Document includes notably the annual financial report, the report by the Board of Directors on corporate governance as well as the reports of the statutory auditors.
The 2016 Registration Document is available on the company's website (www.pixium-vision.com) and on the AMF website (www.amf-france.org). The Registration Document is also available at the registered office of the company: 74 rue du Faubourg Saint Antoine, 75012 Paris.
ABOUT PIXIUM VISION
Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention as well as a rehabilitation period. Following the CE mark for its first bionic retinal implant systems, IRIS®II, Pixium Vision is now conducting a clinical study1 in Human with PRIMA, its new generation sub-retinal miniaturized photovoltaic wireless implant system, for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including the Institut de la Vision in Paris, the Stanford University in California, Moorfields Eye Hospital in London, and Institute of Ocular Microsurgery (IMO) in Barcelona. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” par Bpifrance.
For more information, please visit: www.pixium-vision.com;
And
follow us on: Twitter @PixiumVision;
Facebook www.facebook.com/pixiumvision
LinkedIn
www.linkedin.com/company/pixium-vision
Pixium Vision is listed on Euronext Paris (Compartment C). Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.
Pixium Vision is included in the Euronext CAC All Shares index
Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA – Bloomberg: PIX:FP
Disclaimer:
This press release may expressly or implicitly contain
forward-looking statements relating to Pixium Vision and its activity.
Such statements are related to known or unknown risks, uncertainties and
other factors that could lead actual results, financial conditions,
performance or achievements to differ materially from Vision Pixium
results, financial conditions, performance or achievements expressed or
implied by such forward looking statements.
Pixium Vision
provides this press release as of the aforementioned date and does not
commit to update forward looking statements contained herein, whether as
a result of new information, future events or otherwise.
For
a description of risks and uncertainties which could lead to
discrepancies between actual results, financial condition, performance
or achievements and those contained in the forward-looking statements,
please refer to Chapter 4 "Risk Factors" of the company’s Registration
Document filed with the AMF under number R16-033 on April 28, 2016 which
can be found on the websites of the AMF - AMF (www.amf-france.org)
and of Pixium Vision (www.pixium-vision.com).
IRIS®
is a trademark of Pixium-Vision SA